Dr. Shernan G. Holtan, MD

Dr. Holtan practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Holtan's NPI, 1780664284, was assigned on January 19, 2006. Dr. Holtan graduated from University of Nebraska College of Medicine in 2003. Dr. Holtan holds Minnesota license 46758.

Dr. Holtan's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Holtan's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Holtan is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Holtan to 1 more hospital, 6 medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Holtan practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Holtan's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Holtan's licenses on file in 2 states: Minnesota and Oregon.

CMS data shows 181 Medicare services from Dr. Holtan across 3 procedure codes in 2024, for 51 Medicare patients. Medicare paid $13,237 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 51 Medicare patients who saw Dr. Holtan in 2024. The largest group is 65 to 74, with 37 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Holtan's median patient age at 67, with 45% women.

In 2024, Dr. Holtan wrote 166 Medicare Part D claims for 25 patients. 79% of them were for generic drugs. CMS names the drug for 99 of them, across 5 drugs with 11 or more claims each, at $212,383 in total drug cost. In 2023, CMS named 566 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Holtan for performance year 2024, reported as part of a group. Dr. Holtan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Holtan as offering telehealth.

CMS Open Payments shows 62 general payments to Dr. Holtan from 7 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 49% of the total. Incyte Corporation paid the most, $39,036.

Dr. Holtan graduated from University of Nebraska College of Medicine in 2003.